Flyte Aviation, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VJET research report →
Price Chart
About the company
The company operates private aviation and cardiac electrophysiology businesses. Its aviation business provides short-haul private air travel using Cirrus Vision Jets and private-flight coordination services; its medical business develops technologies for treating cardiac arrhythmias.
- CEO
- David A. Jenkins
- IPO
- 2018
- Employees
- 17
- HQ
- Fort Mill, SC, US
Get TickerSpark's AI analysis on VJET
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $740.95K
- P/E
- -0.01
- PEG
- -0.00
- P/S
- 0.25
- P/B
- 0.05
- EV/EBITDA
- -0.56
- Div Yield
- 0.00%
- Gross Margin
- 29.20%
- Op Margin
- -328.75%
- Net Margin
- -721.09%
- ROE
- -219.68%
- ROIC
- -53.17%
Latest fiscal year · YoY change
- Revenue
- $819.00K+95.0%
- Gross Profit
- $756.00K+100.0%
- Op Income
- $-12,181,000
- Net Income
- $-17,183,000-3.2%
- EPS
- $-159.00+87.5%
- OCF Growth
- +10.5%
- FCF Growth
- +11.0%
- 52W High
- $30.60
- 52W Low
- $0.32
- 50D MA
- $0.99
- 200D MA
- $6.96
- Beta
- 0.28
- RSI (14)
- 24
- Avg Volume
- 539.15K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Ra Medical reported a very small first-quarter revenue base but continued progress on its DABRA clinical and regulatory programs, while also announcing a CFO transition and a strategic alternatives review.· May 16, 2022
- Q1 product sales were $9,000, with a GAAP net loss from continuing operations of $5.5 million, or $0.27 per share.
- The atherectomy pivotal study reached 107 of 125 planned subjects enrolled, and management still targets full enrollment by the end of Q3 2022.
- Management expects DABRA 2.0 510(k) clearance in Q3 2022 and plans to file the DABRA RX 510(k) at the end of this year.
- Ra Medical is also exploring intravascular lithotripsy applications, with additional preclinical work planned over the next few months.
- The company announced CFO Andrew Jackson’s resignation and said the board is reviewing strategic alternatives with an investment bank.
First-quarter 2022 revenue from continuing operations was $9,000, versus $4,000 in the first quarter of 2021. Gross loss was $86,000, compared with $0.4 million in the prior-year quarter. SG&A expense was $2.3 million, down from $3.7 million, and R&D expense was $3.1 million, up from $2.8 million. GAAP net loss from continuing operations was $5.5 million, or $0.27 per share, versus a loss of $6.9 million, or $2.36 per share, a year ago. Adjusted EBITDA was negative $5.1 million, compared with negative $6.0 million. The company used $8.6 million in cash for operating activities and ended the quarter with $17.7 million in cash and cash equivalents. Management said 107 of 125 planned subjects had enrolled in the atherectomy study and continued to target full enrollment by the end of Q3 2022. It also said DABRA 2.0 510(k) clearance is still expected in Q3 2022, the DABRA laser system 510(k) is targeted for Q3 2022, and the DABRA RX 510(k) is targeted for the end of this year.
Will McGuire emphasized progress on building a differentiated vascular portfolio for PAD and framed FDA atherectomy clearance as the top priority because it would expand the addressable market beyond CTOs. He struck a cautiously constructive tone on engineering milestones, saying the company is progressing on DABRA 2.0, the next laser system filing, and early work on intravascular lithotripsy. He also said management and the board are reviewing strategic alternatives to maximize shareholder value, which could lead to a refocus or a new strategic initiative.
Andrew Jackson highlighted that the dermatology business was divested in 2021 and that current results are for continuing operations, with only catheter revenue tied to the clinical study. He cited $9,000 of product sales, $86,000 of gross loss, $2.3 million of SG&A, $3.1 million of R&D, $5.5 million of GAAP net loss from continuing operations, and $17.7 million of cash and cash equivalents at quarter-end. He also said cash used in operations was $8.6 million, including a $600,000 securities litigation settlement and $300,000 from a previously accrued settlement, and noted the February 2022 public offering brought in $9.7 million net proceeds.
Analysts focused on the gap between operating loss and cash burn, and Jackson explained that Q1 cash used included the $600,000 securities litigation settlement and $300,000 from a settlement accrued in prior years. Jeffrey Cohen also asked about the laser system’s capabilities and whether power output could be increased; McGuire said the team believes it has the ability to raise output if needed and that current output is close to literature-referenced levels for Shockwave Medical. On the planned DABRA RX filing, McGuire said it will be an atherectomy-only laser-and-catheter system, while lithotripsy would require a later filing and additional interface work.
The company is making measurable progress on a potentially larger opportunity, with atherectomy-study enrollment at 107 of 125 and another site recently cleared. Management also has multiple near-term technical and regulatory catalysts: DABRA 2.0 clearance targeted for Q3 2022, a DABRA laser filing in Q3, and a DABRA RX filing later this year. The discussion of intravascular lithotripsy suggests a possible longer-term expansion beyond the current atherectomy path.
Revenue remains minimal because commercial catheter shipments are still paused, so the business is dependent on clinical and regulatory progress rather than current sales. Management said COVID-19 is still affecting study timing, and it could not commit to the exact enrollment completion date. The CFO departure and the ongoing strategic alternatives review signal uncertainty about the company’s direction and may imply a need for additional capital or a refocus of the business.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 39.4%
- Shares Outstanding
- 2.10M
- Float Shares
- 827.48K
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ladenburg Thalmann Financial Services Inc. | 4.10K | 0 |
| Catamount Wealth Management | 2.67K | 0 |
| Advisor Group, Inc. | 600 | 0 |
| Next Financial Holdings | 555 | ▲ 555 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 26, 26 | JENKINS DAVID A | other | 40,000 |
| Mar 26, 26 | ANDERSON PHILIP J | other | 40,000 |
| Mar 26, 26 | Arno Andrew | other | 40,000 |
| Mar 26, 26 | Caruso James Joseph | other | 40,000 |
| Mar 26, 26 | COLOMBATTO MARTIN J | other | 40,000 |
| Feb 12, 26 | JENKINS DAVID A | other | 6,998.195 |
| Feb 12, 26 | JENKINS DAVID A | other | 2,491.293 |
| Dec 31, 25 | JENKINS DAVID A | other | 170,000 |
| Dec 5, 25 | Caruso James Joseph | other | 41 |
| Dec 5, 25 | Caruso James Joseph | other | 7.932 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VJET coverage
Recent articles, reports, and earnings notes.
No research on VJET yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VJET report →Flyte Aviation Reports Record Third Quarter 2026 Aviation Revenue Increasing 145% Sequentially
prnewswire.com · Nov 16
Catheter Precision Partners With Two New German Heart Centers
globenewswire.com · Nov 16
Flyte Aviation Launches Flyte Club to Disrupt Jet Cards and Fractional Ownership Programs with Transparent Per-Trip Pricing and Savings Up to 30%
prnewswire.com · Nov 5
Flyte Aviation Executes Letter of Intent to Sell Cardiology Assets
prnewswire.com · Nov 4
Catheter Precision Announces New FDA 510(k) Clearance for its VIVO System, Enabling Use in a Broader Patient Population
globenewswire.com · Nov 2
Flyte Aviation Expands International Operations to Canada
globenewswire.com · Oct 29
Flyte Aviation, One of the Nation's Largest Vision Jet Operators, Congratulates Cirrus Aircraft on Ten Years of Innovation
globenewswire.com · Oct 26
Catheter Precision Announces Publication of Comparative Study Showing LockeT Outperforms Abbott's Perclose Internal Vascular Closure Device
globenewswire.com · Oct 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.